VALN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.520

Open

6.461

VWAP

6.38

Vol

114.89K

Mkt Cap

562.96M

Low

6.305

Amount

732.83K

EV/EBITDA(TTM)

--

Total Shares

86.88M

EV

587.72M

EV/OCF(TTM)

--

P/S(TTM)

2.74

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Show More

Events Timeline

(ET)

2026-03-23

06:50:00

Pfizer and Valneva Announce Lyme Disease Vaccine Trial Results

2026-03-18 (ET)

2026-03-18

08:20:00

Elaris Signs Exclusive Global License Agreement with Valneva

2026-01-19 (ET)

2026-01-19

14:20:00

Valneva Voluntarily Withdraws Ixchiq Vaccine Applications

2025-12-31 (ET)

2025-12-31

11:50:00

Valneva and Serum Institute of India Terminate Chikungunya Vaccine License Agreement

2025-12-10 (ET)

2025-12-10

11:50:00

Valneva Reports Positive Final Data for IXCHIQ Vaccine

2025-08-25 (ET)

2025-08-25

06:53:04

Valneva reveals U.S. FDA has suspended IXCHIQ's license.

News

Newsfilter

17:43 PMNewsfilter

PinnedValneva to Participate in World Vaccine Congress 2026

Globenewswire

03-24Globenewswire

Valneva's Vaccine Trial Fails to Meet Primary Endpoint

NASDAQ.COM

03-23NASDAQ.COM

Valneva's Lyme Disease Vaccine Candidate Shows Over 70% Efficacy

Yahoo Finance

03-23Yahoo Finance

Experimental Lyme Disease Vaccine Shows Over 70% Efficacy

seekingalpha

03-23seekingalpha

Pfizer and Valneva Report Phase 3 Results for Lyme Disease Vaccine

NASDAQ.COM

03-23NASDAQ.COM

Pfizer and Valneva Report Phase 3 Vaccine Trial Results

2 Analyst Rating

Wall Street analysts forecast VALN stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.55

Averages

10.28

High

13.00

Current: 0.000

Low

7.55

Averages

10.28

High

13.00

Jefferies

Buy

maintain

$15

AI Analysis

2026-03-23

New

Reason

Jefferies

Price Target

$15

AI Analysis

2026-03-23

New

maintain

Buy

Reason

Jefferies reiterated a Buy rating and $15 price target on Valneva after the company reported topline results from the Phase 3 VALOR clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405. The firm told investors in a research note that the stock is over-reacting due to headline miss on statistical significance for per-protocol analysis with 28-day post-dose endpoint showing 73.2% vaccine efficacy that missed bar for greater than 20% on the lower bound of 95% confidence interval. Jefferies added that stock weakness presents a buying opportunity with potential path to approval intact.

Guggenheim

Buy

downgrade

$14 -> $13

2025-09-08

Reason

Guggenheim

Price Target

$14 -> $13

2025-09-08

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VALN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Valneva SE (VALN.O) is -8.22, compared to its 5-year average forward P/E of -236.52. For a more detailed relative valuation and DCF analysis to assess Valneva SE's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-236.52

Current PE

-8.22

Overvalued PE

466.21

Undervalued PE

-939.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.72

Current EV/EBITDA

-21.34

Overvalued EV/EBITDA

55.97

Undervalued EV/EBITDA

-54.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.67

Current PS

3.46

Overvalued PS

4.97

Undervalued PS

2.36

Financials

AI Analysis

Annual

Quarterly

Whales Holding VALN

Frazier Life Sciences Management, LP

General American Investors Company, Inc.

Bpifrance Participations SA

CNP Assurances SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Valneva SE (VALN) stock price today?

The current price of VALN is 6.31 USD — it has decreased -2.62

What is Valneva SE (VALN)'s business?

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

What is the price predicton of VALN Stock?

Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is10.28 USD with a low forecast of 7.55 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Valneva SE (VALN)'s revenue for the last quarter?

Valneva SE revenue for the last quarter amounts to NaN USD, decreased

What is Valneva SE (VALN)'s earnings per share (EPS) for the last quarter?

Valneva SE. EPS for the last quarter amounts to USD, decreased

How many employees does Valneva SE (VALN). have?

Valneva SE (VALN) has 676 emplpoyees as of March 26 2026.

What is Valneva SE (VALN) market cap?

Today VALN has the market capitalization of 562.96M USD.